111 results
PRE 14A
SYRS
Syros Pharmaceuticals Inc.
12 Apr 24
Preliminary proxy
4:30pm
of directors with respect to fiscal 2023 included:
drug safety, including the safety of clinical trial participants;
manufacturing and supply chain
8-K
EX-99.1
SYRS
Syros Pharmaceuticals Inc.
8 Jan 24
Regulation FD Disclosure
7:06am
and future clinical trials the requisite safety, efficacy and combinability of its drug candidates; sustain the response rates and durability of response … demonstrated a well-tolerated safety profile 1Amnolake® post-marketing surveillance data on file; 2Data presented at ASH 2017; 3de Botton S., et al
8-K
EX-99.2
SYRS
Syros Pharmaceuticals Inc.
8 Jan 24
Regulation FD Disclosure
7:06am
, and the overall safety profile demonstrated no additive toxicities or new safety signals, and no evidence of increased myelosuppression compared to treatment … the requisite safety, efficacy and combinability of its drug candidates; sustain the response rates and durability of response seen to date with its drug
8-K
EX-1.1
bdie7yhx fy0gv
19 Dec 23
Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants
4:59pm
424B5
gowsnszm9
19 Dec 23
Prospectus supplement for primary offering
4:53pm
8-K
EX-99.1
5nou92p94u8ei87f
6 Dec 23
Regulation FD Disclosure
7:05am
8-K
EX-99.2
kg011a1pmfsa zlp
6 Dec 23
Regulation FD Disclosure
7:05am
8-K
EX-99.2
2jrdl7aw
25 May 23
Regulation FD Disclosure
5:10pm
8-K
EX-99.1
tmdtfyp3
25 May 23
Regulation FD Disclosure
5:10pm
8-K
jcgh t0qmk
12 Dec 22
Regulation FD Disclosure
7:48am
8-K
EX-99.2
5zzs23c
12 Dec 22
Regulation FD Disclosure
7:48am
8-K
EX-99.1
i0mgice6 3t7
12 Dec 22
Regulation FD Disclosure
7:48am